Michal Bar-Natan Zommer, MD
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756 212-241-6756
Michal Bar-Natan, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology). Her focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials in patients with these conditions. As a member of the Myeloproliferative Neoplasms (MPN) program and Adult Leukemia program and a leader of the Acute Lymphoblastic Leukemia program, Dr. Bar-Natan provides care for patients with MPN, acute leukemia, and other hematological malignancies at The Ruttenberg Treatment Center. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as a co-investigator on many other clinical trials with the goal of improving the outcome of patients with MPN and acute leukemia.
In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital, with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms and leukemias. She completed a second research fellowship at Beth Israel Deaconess Medical Center, with a focus on the effect of MUC1 oncoprotein signaling on the biology and immunity of acute myeloid leukemia and multiple myeloma. Dr. Bar-Natan has authored numerous publications, as well as a book chapter on immunotherapeutic strategies in multiple myeloma.
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Essential Thrombocythemia
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Polycythemia Vera
MD, Sackler School of Medicine
Residency, Sheba Medical Center
NYU Medical Center
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Bar-Natan Zommer did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.